Why can’t you lay down after taking TETRACYCLINE (TORQUE) 500MG CAPSULE?
Take TETRACYCLINE (TORQUE) 500MG CAPSULE as advised by your doctor. Lying down right after taking TETRACYCLINE (TORQUE) 500MG CAPSULE can cause oesophagus irritation as well, so don't take it immediately before going to bed.
How long should I take TETRACYCLINE (TORQUE) 500MG CAPSULE?
The usual duration of management is at least 10 days unless otherwise directed by your doctor. Your doctor will decide the correct dose and duration for you depending upon your age, body weight and disease condition.
What precautions have to be taken while taking TETRACYCLINE (TORQUE) 500MG CAPSULE?
TETRACYCLINE (TORQUE) 500MG CAPSULE may increase your sensitivity to sunlight and may cause exaggerated sunburns in hypersensitive persons. Avoid exposure to sunlight or ultraviolet light while taking TETRACYCLINE (TORQUE) 500MG CAPSULE and should discontinue therapy at the first sign of skin discomfort.
What should I avoid while taking TETRACYCLINE (TORQUE) 500MG CAPSULE?
Do not take this medicine with food or milk foods such as milk, yogurt, cheese and ice cream at the same time, as they can make the medicine less effective. Contact your doctor for advice.
Can I stop TETRACYCLINE (TORQUE) 500MG CAPSULE if I feel better?
Although it is common to feel better early in the course of therapy, the medication should be taken exactly as directedby your doctor. Do not stop taking TETRACYCLINE (TORQUE) 500MG CAPSULE early as your infection may return if you do not finish the course of this medicine.
Does TETRACYCLINE (TORQUE) 500MG CAPSULE cause diarrhea?
Yes, TETRACYCLINE (TORQUE) 500MG CAPSULE may cause diarrhea. Drink lots of fluids, such as water or fruit juices to keep yourself hydrated. Do not take any medicine on your own for managing diarrhoea. Contact your doctor if your diarrhoea did not improve or suffering from severe or prolonged diarrhoea which may have blood or mucus in it, this may be a sign of serious bowel inflammation.
How long do I take TETRACYCLINE (TORQUE) 500MG CAPSULE?TETRACYCLINE (TORQUE) 500MG CAPSULE may cause esophageal irritation:
What if I miss a dose of TETRACYCLINE (TORQUE) 500MG CAPSULE?
If you take a missed dose of this medicine (or other medicines which may be used to treat them), take it as soon as you remember. Skip the missed dose and resume to your regular dosing schedule. Doses should be taken at the same time each day to help you remember.
The most common side effects of Tetracycline HCl tablets:
Canine Diabetic Retinopathy in Patients with a History of Pregnant or Breastfeeding: A Case Report
The authors describe a case of pudendal hypertrophic pudendal syndrome (PPD), an autosomal recessive inheritance of diabetes. Although PPD is the most common form of diabetic retinopathy, it can also present with other conditions that affect the eyes, such as glaucoma, retinopathy of prematurity, ocular hypertension, or diabetic retinopathy.
The exact mechanism of action is not fully understood, but the possible contribution of tetracycline to the pathogenesis of PPD is unclear.
Tetracyclines:
Tetracyclines are the most commonly used tetracycline for the treatment of infections caused by susceptible microorganisms (e.g.,Mycoplasma genitaliumandBacillus anthracis). They are also used to treat strep throat, pneumonia, ear infections, and typhoid fever.
Other tetracyclines:
There is no equivalent drug approved for the treatment of tetracycline-resistant.
The use of tetracyclines in the treatment of infections of the bloodstream (including acute tonsillitis, sinusitis, pneumonia, bronchitis, and otitis media) is supported by anecdotal evidence from numerous studies of the use of tetracyclines in the treatment of pneumonia, ear infections, and typhoid fever.
Infections caused by:
The treatment of infections caused byM. genitaliuminfections depends on the organism in question. This is because the infection must be susceptible to the antibiotic tetracycline (e.g., cotrimoxazole).
The drug of choice for the treatment of infections caused byis either tetracycline or sulfamethoxazole-trimethoprim, a combination of sulfamethoxazole (SMZ), trimethoprim (TMP), and minocycline (MMC).
If the causative organism is susceptible to both tetracycline and SMZ, the use of TMP is often recommended. However, this combination can cause serious reactions.
Other infections:
There is no equivalent drug for the treatment of infections caused byinfections. Therefore, infections that require further treatment should be treated with a broad-spectrum antibiotic.
Tetracyclines should not be given to pregnant women and should only be used after consulting a healthcare professional. Although the use of tetracyclines in pregnancy is not recommended by the FDA, the use of tetracyclines in the post-partum period is recommended. It is possible to have a severe pregnancy failure or a life-threatening condition that is resistant to tetracyclines.
The use of tetracyclines in the treatment of infections in nursing mothers should be limited to the indications listed above.
In the treatment of infections caused by
Tetracyclines are often used to treat infections caused byand to treat strep throat, pneumonia, ear infections, and typhoid fever. However, the use of tetracyclines in the treatment of infections caused byis contraindicated, and it should be avoided by pregnant women and nursing mothers.
The use of tetracyclines in the treatment of infections caused by
Tetracyclines are also indicated for the treatment of infections caused byand to treat infections caused by
A number of experiments have demonstrated that the antibiotic tetracycline acts to inhibit the production of the intracellular tetracycline protein in human and mouse cells. This action is in agreement with the previous findings of a significant decrease in the number of intracellular tetracycline molecules in cultured cells in response to the addition of tetracycline to the media of the cultures.
In the present study we show that Tetracycline acts to inhibit the production of intracellular tetracycline by the bacteria L. pneumophila. Our findings provide evidence that this antibiotic acts to inhibit the production of intracellular tetracycline protein in the absence of its activity. Furthermore, the presence of tetracycline in the media of the cultures did not alter the ability of the bacteria to produce intracellular tetracycline, a property which is independent of its effect on the production of intracellular tetracycline.
In conclusion, this study demonstrated that the bactericidal activity of Tetracycline was decreased in the presence of Tetracycline and that the inhibition of the production of intracellular tetracycline by the bacteria L. pneumophila was not associated with the decrease in the ability of L. pneumophila to produce intracellular tetracycline.
Citation:Tombrel M, Burdett M, Tumlack L, et al. (2022) The effect of Tetracycline on the intracellular tetracycline production in L. PLoS ONE 14(4): e012788. https://doi.org/10.1371/journal.pone.012788
Editor:W. H. R. Schuster, The University of Texas Health Science Center at San Antonio, USA
Received:August 16, 2022;Accepted:May 20, 2022;Published:July 13, 2022
Copyright:© 2022omb. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability:All data are within the manuscript and its files.
Funding:The study was funded by the National Institute of General Medical Sciences (NIGMS), Grant Number NNG-GA-20C06903, and the National Institutes of Health R01GM077592, by the National Institute of General Medical Sciences (NIH), Grant Number NIH R01GM077592.
Competing interests:The authors have declared that no competing interests exist.
Metronidazole, a broad-spectrum antibiotic used to treat bacterial infections, is known to inhibit the production of numerous intracellular and extracellular tetracycline molecules []. It has been found to have antimicrobial activity against Gram-positive and Gram-negative bacteria. L. pneumophila, a bacterial pathogen responsible for the spread of bacterial diseases, also produces intracellular tetracycline in the media of the infected and noninfected human and mouse cell cultures. Tetracycline is a drug that is used in the treatment of many infections, but is also used in the treatment of many other bacterial pathogens.
We have previously shown that tetracycline acts to inhibit the production of intracellular tetracycline protein in human and mouse cells []. Our previous study demonstrated that tetracycline acts to inhibit the production of intracellular tetracycline by L. pneumophila, an important pathogen responsible for the development of human and animal diseases. The current study reports that the tetracycline antibiotic Tetracycline acts to inhibit the production of intracellular tetracycline by the bacteria L.
To date, there have been no studies that examined the effect of the antibiotic on the production of intracellular tetracycline. Our previous study of the effect of Tetracycline on the intracellular tetracycline production by L. pneumophila in the presence of the bacteriostatic antibiotic, tetracycline, found that this antibiotic effectively inhibited the growth of the bacteria in the presence of Tetracycline.
The tetracycline-controlled promoters (TACs) are a class of plasmids in the prokaryotic cell. They are often used in the treatment of various pathogenic organisms such as gram positive, gram negative, and oropharyngeal infections (, ). A variety of tetracycline-controlled promoters (TACs) have been developed and widely used in the treatment of many pathogens includingStaphylococcus aureus,Pasteurella multocidaBordetella bronchisepticaHaemophilus influenzae, andHaemophilus parainfluenzae. Most of the currently available tetracycline-controlled promoters have a strong activity against a range of Gram-negative and Gram-positive bacteria and certain fungi. A TAC is a gene product that can be fused with a promoter that binds an inhibitory signal for the induction of a broad range of growth processes including cell wall synthesis, cell division, cell death, and stress responses. A TAC consists of a set of three active promoters.
A TAC that is designed to bind a promoter in a specific manner can activate its own expression. The TAC that is activated by a single promoter can then be used to make a different TAC, or it can be fused with a single gene product in a specific manner. In this manner, a TAC can be used to drive the expression of genes in the host cell, which can then be used to make the host cell responsive to the presence of an external stress, which is known as the inducible expression system.
The promoter that is targeted by a promoter can be used to create a TAC that can then be used to drive the expression of a host gene. For example, the TAC that was used to make the gene product was fused to the promoter of the gene encoding a cell wall synthesis-inducing peptide (CPE-I) that is an anti-inflammatory peptide.
The expression of a host gene in a TAC can be induced by the addition of a TAC in a manner that allows for the induction of the expression of a host gene. In this manner, the TAC can be used to make the host cell responsive to the presence of an external stress and to drive the expression of the host gene in the host cell. For example, the TAC that was used to make the gene product was fused to the promoter of a cell wall synthesis-inducing peptide (CPE-I) that is an anti-inflammatory peptide.
The transcriptional activation of a TAC by a single promoter can be triggered by the addition of a TAC in a manner that allows for the induction of the expression of a host gene.
A TAC that is fused to a promoter can be used to create a TAC that can then be used to make a host cell responsive to the presence of an external stress and to drive the expression of the host gene in the host cell.
Stade de France Pharmacy